Warren Stone is recorded as CEO and Board Member at Neogenomics Inc (NEO) since January 4, 2027 and COO at Neogenomics Inc (NEO). The newest filing on record that lists Warren Stone as COO at Neogenomics Inc (NEO) is dated April 6, 2026. Neogenomics Inc reported in an 8-K filed October 5, 2026 that Warren Stone was appointed member of the Board, effective January 4, 2027. Neogenomics Inc reported in an 8-K filed October 5, 2026 that Warren Stone was appointed Chief Executive Officer, effective January 4, 2027. Neogenomics Inc reported in an 8-K filed March 18, 2025 that Warren Stone was appointed President & Chief Operating Officer, effective April 1, 2025. Equibles holds 5 filed executive changes naming Warren Stone; each is listed under recent activity with its source filing. The proxy statement of Neogenomics Inc reports total compensation of $5,068,830 for Warren Stone in fiscal 2025, including a base salary of $630,069. Disclosed compensation is on record for 5 fiscal years. Warren Stone has spoken on 4 earnings calls across 1 company, most recently for Neogenomics Inc on July 28, 2026. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Chris Smith (CEO and Board Member), Christopher Smith (CEO and Board Member), Tony Zook (CEO, Chairman and Board Member) and 7 others.
“On September 30, 2026, the Board of Directors (the "Board") of the Company approved the appointment of Warren Stone, the Company's current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.”
Neogenomics Inc Form 8-K, filed October 5, 2026
· Read the filing
“On September 30, 2026, the Board of Directors (the "Board") of the Company approved the appointment of Warren Stone, the Company's current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.”
Neogenomics Inc Form 8-K, filed October 5, 2026
· Read the filing
Warren Stone on recent calls
“I want to begin with a brief update on our commercial momentum before turning to the operational progress, including our Lab of the Future initiative that is supporting the launches that Tony just discussed.”
“Our primary focus is the community setting, where approximately 80% of patients seek treatment so that they're close to their support structure. Additionally, most patients live an hour or more from the nearest NTI-designated cancer center.”
“Nineteen of the top 20 pharma companies have oncology as their number one focus area from an R&D investment perspective. And with that as a backdrop, it's a very large and attractive market opportunity.”
